Semaglutide (sodium salt)
目录号 : GC91627Semaglutide is an agonist of glucagon-like peptide 1 receptor (GLP-1R; EC50 = 6.2 pM in a reporter assay using BHK cells expressing the human receptor).
Cas No.:2924330-56-1
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Semaglutide is an agonist of glucagon-like peptide 1 receptor (GLP-1R; EC50 = 6.2 pM in a reporter assay using BHK cells expressing the human receptor).[1] It decreases blood glucose levels in the db/db mouse model of type 2 diabetes (ED50 = <2 nmol/kg). Semaglutide (25 nmol/kg) prevents decreases in the number of dopaminergic neurons in the substantia nigra and increases in lipid peroxidation in the substantia nigra and striatum, as well as improves motor coordination in the rotarod and footprint tests in a mouse model of Parkinson's disease induced by MPTP.[2] It decreases neuronal loss in the hippocampal dentate gyrus and CA1 and CA3 regions and improves motor coordination and grip strength in the beam-walking and hanging wire tests, respectively, in a rat model of stroke induced by permanent middle cerebral artery occlusion (MCAO) when administered at a dose of 10 nmol/kg every other day.[3] Formulations containing semaglutide have been used in the treatment of type 2 diabetes.
References:
[1].Lau, J., Bloch, P., Schäffer, L., et al.Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutideJ. Med. Chem.58(18)7370-7380(2015).
[2].Zhang, L., Zhang, L., Li, L., et al.Neuroprotective effects of the novel GLP-1 long acting analogue semaglutide in the MPTP Parkinson's disease mouse modelNeuropeptides7170-80(2018).
[3].Yang, X., Feng, P., Zhang, X., et al.The diabetes drug semaglutide reduces infarct size, inflammation, and apoptosis, and normalizes neurogenesis in a rat model of strokeNeuropharmacology158107748(2019).
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 0.2431 mL | 1.2155 mL | 2.431 mL |
| 5 mM | 0.0486 mL | 0.2431 mL | 0.4862 mL |
| 10 mM | 0.0243 mL | 0.1215 mL | 0.2431 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。